Dementia and Alzheimer Disease

Eighteen percent of the Alzheimer disease treatment’s study participants are anticipated to be Black/African American and Latinx, according to an announcement from Biogen and Eisai.

The cognitive neurologist at the University of California, San Francisco discussed the complexities in characterizing milder cognitive disorders and the need for more tailored assessments for these patients. [WATCH TIME: 8 minutes]

The founding executive director of the Alzheimer’s Drug Discovery Foundation spoke on the data and developments he is looking forward to seeing in 2022. [WATCH TIME: 3 minutes]

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas discussed how the momentum gained within the Alzheimer community can springboard success going forward. [WATCH TIME: 4 minutes]

The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19 and the need to legitimize these conditions.

Dr Atri lists the common screening tools used to form an AD diagnosis.

Alireza Atri, MD, PhD, describes the pathophysiology of Alzheimer’s disease (AD).

Approximately 300 patients across 30 clinical centers will be included in the 36-week study evaluating the efficacy and safety of sodium oligomannate (GV-971), a medication currently approved for Alzheimer disease in China.

The senior VP of clinical research and deputy chief clinical officer of the neurology business group at Eisai spoke to the recent first enrollment in the Tau NexGen study of the investigational antimicrotubule binding region tau antibody, E2814.

The cognitive neurologist at the University of California San Francisco provided insight on how she’s taken a cognitive neurology approach to the COVID-19 pandemic, and how her background in HIV influenced her recent research. [WATCH TIME: 5 minutes]

Here's what is coming soon to NeurologyLive®.

The clinical hold comes 2 days after an announcement from Denali Therapeutics detailing a partnership with Takeda Pharmaceutical Company to codevelop and cocommercialize the treatment.

The trial will also include another investiartional Eisai agent, the antiamyloid therapy lecanemab, as the background study drug to evaluate the true effect of E2814 has on patients with dominantly inherited Alzheimer disease.

Neurology News Network for the week ending January 22, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

The study of 251 hospitalized patients with COVID-19 found that biomarkers were elevated to levels that were similar to—or even higher than—those observed in patients with Alzheimer disease.

In cases with reported behavioral variant AD, investigators observed AD-like pattern with relative frontal sparing and a relatively more behavioral variant frontotemporal dementia-like pattern with both posterior and anterior involvement.

The professor of neurology at NYU Langone Grossman School of Medicine discussed future research for neurological complications in patients hospitalized with COVID-19 infection. [WATCH TIME: 4 minutes]

Investigators measured p-tau181 and p-tau231 levels with in-house single molecule array assays and cognition with the Mini-Mental State Examination.

Those who had crossovers of ALS and frontotemporal dementia had structural and functional resemblance to the patterns of damage of those with only behavioral variant frontotemporal dementia.

A recent study found that blood markers of brain damage were higher in patients with COVID-19 than in those with Alzheimer disease. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The research also identified small subcortical cerebral amyloid angiopathy-associated acute ischemic stroke lesions as risk factors for death in these patients.

Regions typically affected by Alzheimer disease-related neurodegeneration were similarly protected by the carriership of at least 1 ε2 allele, regardless of their load.

Neurology News Network for the week ending January 15, 2022. [WATCH TIME: 4 minutes]

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 14, 2022.

Jennifer Frontera, MD, professor of neurology, NYU Langone Grossman School of Medicine, discussed findings from a recently published study investigating neurological complications in hospitalized patients with COVID-19.

Jeffrey L. Cummings, MD, ScD, comments on the unmet needs and future outlook for the Alzheimer’s treatment landscape.

Dr Cummings relays how testing methods influence the treatment course for Alzheimer’s disease.